/
Immunology
Autoimmune Disease
73
Pipeline Programs↗
100
Active Trials↗
40
Companies Involved↗
Autoimmune Disease is a moderately active landscape with 73 programs across 40 companies. The most active players are Nanjing Legend Biotech Co., Novartis, China Immunotech (Beijing) Biotechnology Co., Ltd..
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical23
Phase 137
Phase 213
Phase 3
No programs
Approved
No programs
Analysis
Modality Breakdown
57programs
Small molecule2849%
Cell therapy2239%
Monoclonal antibody47%
Protein / enzyme24%
Vaccine12%
Modality classified for 100% of 73 pipeline programs.
Analysis
Trial Status
136
clinical trials
Recruiting60 · 44%
Not yet recruiting30 · 22%
Completed20 · 15%
Unknown status7 · 5%
Active, not recruiting6 · 4%
Terminated4 · 3%
Other9 · 7%
Clinical Trials
Trial Activity
136 trials
An Exploratory Clinical Study of CD19 CAR NK Cell Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases
Recruiting·—·Phase 1·NCT06464679·72 enrolled
A Study of OL-108 in Relapsed/Refractory Autoimmune Diseases
Recruiting·—·Phase 1·NCT06980597·44 enrolled
Page 1 of 10
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)